Walter Mingrone

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Richard Herrmann, G. Bodoky, Thomas Ruhstaller et al. · Journal of Clinical Oncology · 2007 · 590 citations

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

Walter Weder, Rolf A. Stahel, J. Bernhard et al. · Annals of Oncology · 2007 · 318 citations · Full text

Surgical Oncology, Malignant Pleural Mesothelioma, Medicine +6

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Michael Pfreundschuh, Anthony D. Ho, Eva Cavallin‐Ståhl et al. · The Lancet Oncology · 2008 · 221 citations

Hematological Malignancy, Lymphoid Neoplasia, Maximum Tumour +9

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

Markus Borner, Dieter Koeberle, Roger von Moos et al. · Annals of Oncology · 2008 · 127 citations · Full text

Swiss Group, Oncology, Gastrointestinal Oncology +10